NB 004 - Ningbo Newbay Medical Technology
Alternative Names: GDC 0570 - Ningbo Newbay Medical Technology; NB004 - Ningbo Newbay Medical TechnologyLatest Information Update: 17 Jun 2024
At a glance
- Originator Ningbo NewBay Medical Technology
- Class Antineoplastics
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Solid tumours
Most Recent Events
- 05 Apr 2024 Adverse events and pharmacokinetics data from a phase I trial in Solid tumour presented at the 115th Annual Meeting of the American Association for Cancer Research, 2024 (AACR-2024)
- 05 Apr 2024 Pharmacodynamics data from a preclinical studies in Solid tumour presented at the 115th Annual Meeting of the American Association for Cancer Research, 2024 (AACR-2024)
- 01 Oct 2021 Phase-I clinical trials in Solid tumours (Late-stage disease) in USA (PO) (NCT05036291)